Somebody else pays first: management describes counterparties putting their own money down ahead of delivery
The model's full reasoning — Q3 2016 call → NOWe need to determine if management describes counterparties putting their own money or resources at risk before receiving what they are paying for, and whether this is presented as happening now in real dealings. The transcript is about Fate Therapeutics, a biotech company. They discuss clinical trials, product candidates, partnerships, etc. The question is about pre-funding by customers or partners. Look for any mention of deposits, prepayments, upfront fees, milestone payments, etc. The company has a collaboration with Juno Therapeutics, which provides research funding. But that is a partnership where Juno pays for research, not necessarily a customer pre-funding for delivery. The revenue from Juno is mentioned as $1 million for both quarters. That is likely research funding, not a customer paying for a product. The company also has partnerships with Memorial Sloan-Kettering, but that is licensing and collaboration, not pre-funding. The question specifically asks about counterparties putting their own money or resources at risk before receiving what they are paying for. In the transcript, there is no mention of customers placing deposits, prepayments, or any advance commitments. The company is a biotech developing therapies, so its "customers" would be patients or healthcare providers, but they don't pay in advance. The revenue comes from collaborations, which are typically research funding. Management does not describe any phenomenon of counterparties pre-funding the company. The only mention of funding is from Juno, which is a strategic research collaboration, but that is not a customer paying for a product; it's a partner funding research. Also, the company has debt and cash, but that's not from customers. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
SYM · Q3 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing real advance commitments from customers: the $11.3 billion backlog (more than doubled), strong deferred revenue on the balance sheet representing a "very significant cost float," and contracts that lock in commitments with restricted changes. Revenue is recognized on a percentage-of-completion basis during deployment, meaning payments 18 months ahead of acceptance. This is framed as an active benefit enabling confident scaling, not a routine or historical norm. They also note improved supplier terms, but the customer-side pre-funding via deferred revenue and backlog is explicitly highlighted as occurring now. This meets the criteria for counterparties committing capital ahead of delivery.
EVGO · Q2 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing the eXtend model with Pilot and GM where the customer (Pilot/GM) incurs the upfront capital expenditures for the charging infrastructure, while EVgo receives ongoing revenues from operations, maintenance, and services. This is presented as an actual, current business arrangement that provides EVgo with immediate cash flow and contracted revenues, not as a future hope or industry norm. Cathy Zoi notes the agreement exceeds IRR hurdles and provides near-term revenue, and Olga Shevorenkova explains the customer funds the build-out, enabling EVgo to generate margin as developer and operator.
BLZE · Q3 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing B2 Reserve as a capacity-based pricing program that includes premium support and free data migration, with revenue ramping in Q3. Frank notes B2 Reserve contracts are "effectively committed contracts," and Gleb calls them "committed contracts" in response to an investor question. This is presented as occurring now, with "initial ramp in demand" and "revenue increasing each month of Q3," not as a future plan or industry norm. The capacity-reservation aspect aligns with the described phenomenon of counterparties committing capital in advance.